J&J buys Firefly Bio for $1 billion to target KRAS solid tumors

Johnson & Johnson acquired Firefly Bio for $1 billion in cash, adding a degrader antibody conjugate platform to target some of the most difficult-to-treat solid tumors.

Johnson & Johnson completed its $1 billion acquisition of Firefly Bio on Wednesday, adding a degrader antibody conjugate platform to target KRAS-driven solid tumors where patients face significant unmet need.

"The completion of this acquisition marks an important step in advancing new approaches to better address difficult-to-treat solid tumors," said John Reed, M.D., Ph.D., Executive Vice President of Innovative Medicine R&D at Johnson & Johnson.

The deal, accounted for as an asset acquisition, will result in an in-process research and development charge of about $1 billion in the third quarter of 2026. J&J expects the transaction to dilute adjusted operational earnings per share by roughly $0.46 in 2026 and $0.08 in 2027, the company said Wednesday.

The acquisition deepens J&J's capabilities in next-generation antibody engineering and broadens its strategy for tackling complex tumor biology. The Firelink DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, enabling targeted activity while preserving healthy tissue — a key limitation of many current treatment approaches.

The deal shows J&J's push into precision oncology as the pharmaceutical giant seeks to expand beyond its existing portfolio of cancer treatments. Firefly Bio's technology combines antibody targeting with protein degradation, a mechanism that has attracted significant investment from large pharma companies seeking more effective solid tumor therapies.

KRAS mutations are among the most common oncogenic drivers in cancer, occurring in roughly 25 percent of all tumors, according to published research. Despite recent advances with KRAS G12C inhibitors, patients with other KRAS mutations continue to face limited treatment options, creating a substantial market opportunity for next-generation approaches.

J&J said the transaction closed on July 29, 2026, and that it expects the deal to dilute adjusted earnings by $0.46 per share this year and $0.08 per share in 2027. The company lowered its full-year 2026 profit forecast to reflect the deal's dilutive impact, according to a regulatory filing.

This article is for informational purposes only and does not constitute investment advice.